Background: The Impella® percutaneous left ventricular assist device has been available in
Japan since 2017. This is the first large-scale registry study to analyze the efficacy and …

Objective: Impella 5.5 (Abiomed, Danvers, MA, USA) is a temporary mechanical circulatory
support device used for patients in cardiogenic shock. This review provides a …

In patients at high risk for haemodynamic instability during percutaneous coronary
intervention (PCI), practitioners are increasingly opting for prophylactic mechanical …

Aims We aimed to detail the early clinical experience with pVAD 5.5 at a large academic
medical centre. Impella® 5.5 (Abiomed) is a temporary peripherally inserted left ventricular …

Percutaneous mechanical circulatory support (pMCS) is increasingly used in patients with
poor left-ventricular (LV) function undergoing elective high-risk percutaneous coronary …

Background PROTECT IV is a current enrolling randomized controlled trial evaluating high-
risk percutaneous coronary intervention (HR-PCI) with prophylactic Impella versus no …

BACKGROUND: There are limited data on the clinical characteristics and outcomes of
patients who require prolonged mechanical circulatory support (MCS) after Impella …

Background The role of acute mechanical circulatory support (aMCS) in patients with stress-
induced cardiomyopathy (SIC) complicated by cardiogenic shock (CS) is not well studied …

Objectives To evaluate the procedural results and in‐hospital outcomes of percutaneous
coronary intervention (PCI) for chronic total occlusion (CTO) in patients with reduced left …

The use of mechanical circulatory support (MCS) in chronic total occlusion (CTO)
percutaneous coronary intervention (PCI) has received limited study. We analyzed the …